ReviewAnnals of medicine2025
Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Review
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- LPIN2 contributes to tyrosine kinase inhibitor resistance via activation of PI3K pathway.Translational lung cancer research · 2026Article
- Single-cell transcriptomic analysis identifies a tumor-enriched GIMAP7⁺ CD4⁺ naïve T cell population with a unique immunoregulatory state in lung adenocarcinoma.Functional & integrative genomics · 2026Article
- High-fidelity super-resolution CT radiomics for non-invasive EGFR mutation prediction in lung adenocarcinoma: a multi-center pooled analysis.La Radiologia medica · 2026Article
- ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma.Respiratory research · 2026Article
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Article
- Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer.Frontiers in cell and developmental biology · 2026Review
- Research progress of EGFR-TKI resistance mechanism and treatment strategy in non-small cell lung cancer.American journal of cancer research · 2026Review
- PTPN9 dephosphorylates IGF1RJournal of experimental & clinical cancer research : CR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) have revolutionized the treatment landscape for Non-Small Cell Lung Cancer (NSCLC). However, resistance invariably curtails their long-term efficacy. This comprehensive review delineates the intricate mechanisms underpinning EGFR TKI resistance and the evolving therapeutic counterstrategies. We present a panoramic atlas of resistance mechanisms, encompassing on-target resistance, bypass pathway activation, histologic transformation, and metabolic reprogramming, alongside their clinical classification. The discussion extends to the integrated diagnostic technologies facilitating resistance detection, including multi-dimensional biopsy approaches and multi-omics fusion analysis. We critically evaluate precision therapeutic approaches tailored to specific resistance alterations, such as C797S mutations and mesenchymal-epithelial transition amplification, and explore the burgeoning field of novel agents like fourth-generation TKIs and antibody-drug conjugates (ADCs). Furthermore, innovative combination strategies and the challenges within resistance management systems, including toxicity profiles and unresolved scientific questions, are examined. A profound understanding of EGFR resistance mechanisms and the continuous refinement of therapeutic paradigms are paramount for improving the prognosis of NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.